Lilly steps up to rival Pfizer, Novartis with Verzenio breast cancer approval

28th September 2017 Uncategorised 0

For the second time in just over six months, there’s a newcomer in the next-generation class of CDK 4/6 breast cancer medicines. The FDA on Thursday greenlighted Eli Lilly’s Verzenio, better known as abemaciclib, which will now duke it out with Pfizer’s Ibrance and Novartis’ Kisqali in HR-positive, HER2-negative disease.

More: Lilly steps up to rival Pfizer, Novartis with Verzenio breast cancer approval
Source: fierce